US · BDRX · BIOTECHNOLOGY
Biodexa Pharmaceuticals Plc (BDRX) intrinsic value and stock valuation
$1.88as of 2026-11-21 · Mkt cap 1.19M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Biodexa Pharmaceuticals Plc DCF and intrinsic value
InvestorsCraft values BDRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BDRX’s statements →
Biodexa Pharmaceuticals Plc Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2012–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $380K | $700K | $580K |
| Operating income | -$-8.27M | -$-9.2M | -$-8.01M | -$-8.93M | -$-7M |
| Net income | -$-6.24M | -$-5.73M | -$-7.08M | -$-7.66M | -$-5.46M |
| EPSd | -$-312M | — | — | — | — |
| Operating cash flow | -$-5.39M | -$-12.26M | -$-6.83M | -$-7.05M | -$-6.01M |
| Capital expenditure | -$0.00 | -$-770K | -$-260K | -$-60K | -$-320K |
| Free cash flow | -$-5.4M | -$-13.04M | -$-7.09M | -$-7.11M | -$-6.33M |
| Total assets | $18.2M | $14.8M | $10.5M | $5.53M | $12.9M |
| Total debt | $60K | $730K | $460K | $620K | $770K |
| Net debt | -$-8.46M | -$-940K | -$-5.51M | -$-2.21M | -$-9.29M |
| Total equity | $11.4M | $8.32M | $4.68M | $3.16M | $10.5M |
| Cash and short-term investments | $8.52M | $1.67M | $5.97M | $2.84M | $10.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $380K | $700K | $580K |
| Cost of revenue | $180K | $5.44M | $4.07M | $5.11M | $4.65M |
| Gross profit | -$-180K | -$-5.44M | -$-3.69M | -$-4.41M | -$-4.08M |
| Research and development expenses | $3.73M | $5.44M | $4.07M | $5.11M | $4.65M |
| Selling, general and administrative expenses | $4.84M | $3.79M | $4.34M | $4.54M | $2.95M |
| Other expenses | -$-480K | -$-5.47M | -$-4.08M | -$-5.13M | -$-4.68M |
| Operating expenses | $8.08M | $3.76M | $4.33M | $4.52M | $2.92M |
| Cost and expenses | $8.27M | $9.2M | $8.39M | $9.63M | $7.58M |
| Interest income | $90K | $0.00 | $80K | $30K | $0.00 |
| Interest expense | $70K | $20K | $40K | $50K | $40K |
| Depreciation and amortization | $180K | $120K | $280K | $170K | $400K |
| Ebitda | -$-8.08M | -$-9.08M | -$-7.16M | -$-8.26M | -$-5.66M |
| Operating income | -$-8.27M | -$-9.2M | -$-8.01M | -$-8.93M | -$-7M |
| Total other income/expenses, net | $1.92M | $3.22M | $530K | $440K | $890K |
| Income before tax | -$-6.35M | -$-5.98M | -$-7.49M | -$-8.49M | -$-6.11M |
| Income tax expense | -$-100K | -$-250K | -$-410K | -$-830K | -$-650K |
| Net income | -$-6.24M | -$-5.73M | -$-7.08M | -$-7.66M | -$-5.46M |
| Weighted average shares outstanding | $20K | $0.00 | $0.00 | $0.00 | $0.00 |
| Weighted average diluted shares outstanding | $20K | $0.00 | $0.00 | $0.00 | $0.00 |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $8.52M | $1.67M | $5.97M | $2.84M | $10.1M |
| Net receivables | $220K | $710K | $700K | $330K | $30K |
| Inventory | $0.00 | $0.00 | -$-700K | $0.00 | $0.00 |
| Total current assets | $12.4M | $8.81M | $7.03M | $4.69M | $11.8M |
| Property, plant and equipment, net | $90K | $320K | $570K | $830K | $1.15M |
| Goodwill and intangible assets | $5.64M | $5.65M | $2.94M | $10K | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $5.73M | $5.97M | $3.51M | $840K | $1.15M |
| Total assets | $18.2M | $14.8M | $10.5M | $5.53M | $12.9M |
| Accounts payable | $100K | $710K | $310K | $340K | $480K |
| Short-term debt | $60K | $610K | $170K | $160K | $150K |
| Deferred revenue | $570K | $1.47M | $0.00 | $200K | $0.00 |
| Total current liabilities | $6.12M | $5.03M | $5.57M | $1.9M | $1.84M |
| Long-term debt | $0.00 | $120K | $290K | $460K | $620K |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $640K | $1.42M | $290K | $460K | $620K |
| Capital lease obligations | $60K | $730K | $460K | $620K | $770K |
| Total liabilities | $6.76M | $6.46M | $5.86M | $2.36M | $2.46M |
| Common stock | $14.1M | $6.69M | $1.19M | $110K | $100K |
| Retained earnings | -$-102.62M | -$-150.42M | -$-144.77M | -$-135.34M | -$-127.8M |
| Accumulated other comprehensive income (loss) | $1.19M | $53M | $61.5M | $53M | $53M |
| Total equity | $11.4M | $8.32M | $4.68M | $3.16M | $10.5M |
| Total investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $60K | $730K | $460K | $620K | $770K |
| Net debt | -$-8.46M | -$-940K | -$-5.51M | -$-2.21M | -$-9.29M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-6.38M | -$-5.73M | -$-7.08M | -$-7.66M | -$-5.46M |
| Depreciation and amortization | $180K | $250K | $280K | $340K | $400K |
| Stock-based compensation | $170K | $280K | $30K | $120K | $90K |
| Change in working capital | $1.68M | -$-3.74M | -$-50K | $520K | -$-620K |
| Accounts receivable | $2.57M | -$-5.97M | $360K | $10K | -$-490K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-890K | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | -$-5.39M | -$-12.26M | -$-6.83M | -$-7.05M | -$-6.01M |
| Investments in property, plant and equipment | -$-680K | -$-10K | -$-30K | -$-60K | -$-320K |
| Acquisitions, net | $20K | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-660K | -$-600K | -$-270K | -$-220K | -$-280K |
| Common stock issued | $13.5M | $8.31M | $10.4M | $240K | $9.04M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $12.8M | $8.56M | $10.2M | $50K | $8.8M |
| Net change in cash | $6.97M | -$-4.3M | $3.13M | -$-7.22M | $2.51M |
| Cash at end of period | $8.52M | $1.67M | $5.97M | $2.84M | $10.1M |
| Operating cash flow | -$-5.39M | -$-12.26M | -$-6.83M | -$-7.05M | -$-6.01M |
| Capital expenditure | -$0.00 | -$-770K | -$-260K | -$-60K | -$-320K |
| Free cash flow | -$-5.4M | -$-13.04M | -$-7.09M | -$-7.11M | -$-6.33M |
Line items
Line items
Line items
About Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
- CEO
- Stephen Anthony Stamp
- Employees
- 11
- Beta
- 1.21
Explore
Frequently asked questions
What is the intrinsic value of Biodexa Pharmaceuticals Plc (BDRX)?
InvestorsCraft does not currently publish an intrinsic value for BDRX. How the IC value is calculated.
Is BDRX undervalued?
InvestorsCraft does not publish an undervaluation signal for BDRX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.